|
Responder status, n (%)
| |
|
Full
|
26/33 (79%)
|
|
Partial
|
3/33 (9%)
|
|
None
|
4/33 (12%)
|
|
Mean time to response, days ± SD, (range)
| |
|
Full response (n = 25)
|
15 ± 18 (1–83)
|
|
Partial response (n = 17)
|
11 ± 13 (2–46)
|
|
Median time to full response, days
|
9
|
|
Median time to partial response, days
|
5
|
|
Mean dosage at time of response, mg/day
| |
|
Full response
|
60 ± 47
|
|
Partial response
|
32 ± 15
|
|
Median dosage at time of response, mg/day
| |
|
Full response
|
50
|
|
Partial response
|
25
|
|
Modal daily dosage for full response, mg/day
|
25
|
|
% of patients in the 12.5–50-mg/day range
|
65
|
|
Modal dosage at time of partial response, mg/day
|
25
|
|
% of patients in the 12.5–50-mg/day range
|
100
|
|
Improvements in nightmares
| |
|
Full cessation of nightmares
|
17/18 (94%)
|
|
Improvements in intrusions
| |
|
Full cessation of intrusions
|
26/33 (79%)
|
|
Partial improvement
|
3/33 (9%)
|
|
No improvement
|
4/33 (12%)
|
